Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

NOV 08 2022

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C. , Nov. 08, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the third quarter ended September 30, 2022 .
NOV 01 2022

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

MORRISVILLE, N.C. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 . The company will host a conference call and webcast at 8:30 a.m.

btn News